Company intelligence / Profile preview

SignPost BioTechnologies

Kingston, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

BreastDefense achieved 99% accuracy for identifying all major subtypes of breast cancer from stages 1-4, with 99% accuracy for both false positive and false negative results[1]. This contrasts with mammography, which has error rates up to 30% false positive and 20% false negative[1].

Therapeutic areas: Oncology
Modalities: Molecular diagnostic test
Industry: Molecular Diagnostics

Partnerships

LabCorp (contracted for test development)Queens University in Kingston, Ontario, Canada (initial discovery collaboration)

Beyond the preview

Go deeper on SignPost BioTechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SignPost BioTechnologies.

Explore the full profile